107 related articles for article (PubMed ID: 35698008)
21. Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma.
Lapke N; Lu YJ; Liao CT; Lee LY; Lin CY; Wang HM; Ng SH; Chen SJ; Yen TC
Oncotarget; 2016 Jul; 7(28):44194-44210. PubMed ID: 27283772
[TBL] [Abstract][Full Text] [Related]
22. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
[TBL] [Abstract][Full Text] [Related]
23. The High Expression of p53 Is Predictive of Poor Survival Rather
Jin Y; Zhao X; Song X; Wang R; Fan Z; Wang P; Yang M; Zhou F; Bao Q; Wang L
J Oncol; 2023; 2023():3801526. PubMed ID: 36660245
[No Abstract] [Full Text] [Related]
24. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the Epstein-Barr virus and tumor suppressor gene p53 gene in nasopharyngeal squamous cell carcinoma.
Liu J; Liu Y; Zhang Z; Sun H; Ji X; Li B; Zhou X; Gai P
J Cancer Res Ther; 2019; 15(2):426-436. PubMed ID: 30964122
[TBL] [Abstract][Full Text] [Related]
26. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
Sung YN; Kim D; Kim J
Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
[TBL] [Abstract][Full Text] [Related]
27. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
[TBL] [Abstract][Full Text] [Related]
28. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
29. Primary tumors of the external and middle ear. I. Introduction and clinicopathologic study of squamous cell carcinoma.
Chen KT; Dehner LP
Arch Otolaryngol; 1978 May; 104(5):247-52. PubMed ID: 646716
[TBL] [Abstract][Full Text] [Related]
30. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731
[TBL] [Abstract][Full Text] [Related]
31. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
32. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
[TBL] [Abstract][Full Text] [Related]
33. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.
Tornesello ML; Buonaguro L; Buonaguro FM
Gynecol Oncol; 2013 Mar; 128(3):442-8. PubMed ID: 23168175
[TBL] [Abstract][Full Text] [Related]
34. Non-disruptive mutation in
Huang M; Jin J; Zhang F; Wu Y; Xu C; Ying L; Su D
Ann Transl Med; 2020 Mar; 8(6):316. PubMed ID: 32355760
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance in oral cavity squamous cell carcinoma of pathogenic somatic mitochondrial mutations.
Lai CH; Huang SF; Liao CT; Chen IH; Wang HM; Hsieh LL
PLoS One; 2013; 8(6):e65578. PubMed ID: 23799027
[TBL] [Abstract][Full Text] [Related]
36. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
37. [Bilateral squamous carcinoma of the external auditory canal--a case report].
Dorobisz K; Kubacka M; Zub K; Dorobisz T; Janczak M; Roszkowska A; Zatoński T; Kręcicki T; Frączek M
Pol Merkur Lekarski; 2015 Aug; 39(230):106-8. PubMed ID: 26319385
[TBL] [Abstract][Full Text] [Related]
38. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
39. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
40. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
